Reports Q3 revenue $73.8M, consensus $72.66M. “For the third quarter of 2023, I am pleased by our strong financial results, including total revenue of $73.8M and adjusted EBITDA of $2.0M, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, we are grateful to be in a position to raise our full year 2023 revenue guidance range and reiterate our full year 2023 adjusted EBITDA guidance range. We are also encouraged by our bookings results through Q3 2023, which are in line with our expectations,” said Dan Burton, CEO of Health Catalyst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCAT:
- Health Catalyst Reports Third Quarter 2023 Results
- Health Catalyst Acquires ERS, Bolsters Tech-Enabled Managed Services Offering with Data Abstraction and Oncology Registry Management Capabilities
- Health Catalyst price target lowered to $8 from $13 at RBC Capital
- Health Catalyst sees 2023 revenue $291M-$296M, consensus $293.78M
- Health Catalyst sees Q4 revenue $70.1M-$75.1M, consensus $73.96M
